Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + REGN2810 in relapsed/refractory multiple myeloma
2017-001431-39Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab and cemiplimab in multiple myeloma (MM), sponsored by Sanofi. Primary endpoint: Dose Limiting Toxicities (DLTs). Started Jun 2017; status: completed.
02
Drugs
isatuximabcemiplimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-001431-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001431-39.